GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with of Diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the 2022 China Nieman Pick Medical Exchange and Sixth Patient Association will be held on August 13, 2022 in Xiamen, China.
“We are thrilled to be part of a meeting like this, which represents an important opportunity to connect with patients, caregivers and all those dedicated to advancing research, understanding and awareness of the disease. NPC in China. We are wholeheartedly committed to advancing the clinical development of Trappsol® Cyclo™ for the treatment of NPCs and we look forward to engaging with our global NPC community,” commented Lise Kjems, MD, PhD, Cyclo Therapeutics Chief Medical Officer.
This event focused on physicians, researchers, and patients will discuss Niemann-Pick Type C (NPC) disease and the latest research findings for diagnosis and treatment. As part of the event, Dr. Kjems will discuss the company’s proprietary formulation of Hydroxypropyl Beta Cyclodextrin, Trappsol® Cyclo™, administered intravenously, and its clinical development program for the treatment of PCNs. The session with Dr. Kjems will take place on Saturday, August 13 at 5:00 p.m. China (GMT+8) / 5:00 a.m. ET.
“In China, we believe that thousands of patients are affected by NPC and we need new therapies to help ease the burden of this deadly disease on patients and caregivers. We appreciate Cyclo’s support to engage with our community to learn more about our patients and their treatment experiences, and to advance medical research to help patients and their families here and around the world,” commented Zhang Aijun, head of China Niemann-Pick. Disease Association, one of the co-sponsors, general secretary of Jiujiang Volunteer Service Association.
About the Chinese NPC Association
The Chinese Niemann-Pick Disease Association was founded in October 2010. It is currently the only NGO in China serving Niemann-Pick disease patients, dedicated to providing domestic Niemann-Pick disease patients Niemann-Pick disease psychological care and medical support, to popularize public awareness of Niemann-Pick disease. Niemann-Pick disease, to promote national medical research on Niemann-Pick disease, and to advocate for the social security system to pay attention to and protect patients with Niemann-Pick disease.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Trappsol of the company® Cyclo™, an orphan drug designated product in the United States and Europe, is being studied in a pivotal Phase 3 clinical trial for Niemann-Pick disease type C, a rare and fatal genetic disorder, (https://www.clinicaltrials.gov/ NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company plans a Phase 2 clinical trial with Trappsol® Intravenous Cyclo™ in Alzheimer’s disease based on encouraging data from an expanded access program for late-onset Alzheimer’s disease (NCT03624842). Additional indications for the active ingredient of Trappsol® Cyclo™ are under development. For more information, visit the Company’s website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about the Company’s current expectations regarding future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offer and the intended use of the proceeds of the offer. . Statements that are not historical facts, such as “anticipates”, “believes”, and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed or implied by such statements. Factors that could affect the Company’s future performance include the Company’s ability to raise additional capital to expand its business as planned, success in obtaining regulatory approval for clinical protocols, recruitment of sufficient number of patients in clinical trials, unforeseen difficulties in demonstrating the efficacy of biopharmaceuticals, success in attracting additional customers and profitable contracts, and the regulatory risks associated with the production of food and pharmaceutical-grade products . These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements as a result of new information or future events.
